Postinfectious Cough Management

Diagnosis and Treatment

• The American Thoracic Society recommends that postinfectious cough be diagnosed based on a timeline of initial URI symptoms for 3 days, followed by cough for 7 days, and clinical presentation, which occurs when cough persists for at least 3 weeks but not more than 8 weeks following an acute respiratory infection 1, 2
• Key features excluding bacterial infection include non-purulent sputum, no fever, clear lungs except transient wheezes that clear with coughing, and no crackles suggesting pneumonia, in an otherwise healthy nonsmoker 1, 3, 4, 5
• The American College of Chest Physicians recommends that antibiotics, such as amoxicillin or azithromycin, are explicitly contraindicated because therapy with antibiotics has no role in postinfectious cough, as the cause is not bacterial infection 1, 3, 2
• Prednisone is reserved for severe paroxysms of postinfectious cough when other common causes have been ruled out, and the guideline-recommended treatment algorithm starts with inhaled ipratropium, then considers inhaled corticosteroids if quality of life is affected 1, 3, 2

Treatment Options

• The American Thoracic Society suggests that supportive care with over-the-counter preparations, such as guaifenesin, is the most appropriate initial management for acute cough following viral URTI 4, 5
• Guaifenesin is FDA-approved to help loosen phlegm and thin bronchial secretions to make coughs more productive, and it remains a safe, nonprescription option that aligns with the patient's mild symptoms and the self-limited nature of postinfectious cough 4, 5
• Inhaled ipratropium bromide may be considered if cough persists or worsens, and inhaled corticosteroids may be considered if quality of life is affected despite ipratropium 1, 3, 2

Common Pitfalls to Avoid

• The American College of Chest Physicians recommends that antibiotics should not be prescribed for postinfectious cough unless there is clear evidence of bacterial sinusitis or early pertussis infection 1, 3, 2
• Prednisone should not be jumped to for mild postinfectious cough, and it should be reserved for severe cases that have failed other therapies 1, 3, 2

Management of Postinfectious Cough

Initial Treatment Approach

• The American College of Chest Physicians recommends inhaled ipratropium bromide 2-3 puffs four times daily as the next step when quality of life is affected in patients with postinfectious cough that persists or worsens after 1-2 weeks of supportive care 6

Second-Line and Third-Line Treatment

• The American College of Chest Physicians states that therapy with antibiotics has no role unless there is clear evidence of bacterial sinusitis or early pertussis infection, and inhaled corticosteroids should only be used after ipratropium has been tried, not as initial therapy 6

Diagnostic Considerations Beyond 8 Weeks

• If the cough persists beyond 8 weeks, consider diagnoses other than postinfectious cough, and systematically evaluate for Upper airway cough syndrome (UACS), Asthma, and GERD, with expected timeframes for response varying by condition 6, 7, 8, 9

Treatment of Alternative Diagnoses

• For Upper airway cough syndrome (UACS), start a first-generation antihistamine-decongestant combination, with improvement typically seen within days to 1-2 weeks 7
• For Asthma, consider bronchoprovocation challenge or empiric trial of inhaled corticosteroids and beta-agonists, with response potentially taking up to 8 weeks 7, 8
• For GERD, initiate high-dose PPI therapy (omeprazole 40 mg twice daily) with dietary modifications, with response potentially requiring 2 weeks to several months 9

Multifactorial Causes of Chronic Cough

• Chronic cough is frequently multifactorial, and the cough will not resolve until all contributing causes have been effectively treated, with partial improvement occurring with one treatment, continuing that therapy and adding the next intervention in the algorithm rather than stopping and switching 7

Management of Persistent Post-Infectious Cough

Diagnosis and Treatment

• The American Thoracic Society suggests that a chest X-ray should be ordered if cough persists beyond 8 weeks, or if any hemoptysis, fever, weight loss, or night sweats develop 10
• The European Respiratory Society recommends that upper airway involvement (post-nasal drip/upper airway cough syndrome) be treated with a first-generation antihistamine-decongestant combination, such as brompheniramine/pseudoephedrine or chlorpheniramine/phenylephrine, and an intranasal corticosteroid spray, such as fluticasone or mometasone 10, 11
• The American College of Chest Physicians suggests that inhaled corticosteroids, such as fluticasone 220 mcg or budesonide 360 mcg twice daily, be considered if quality of life remains significantly affected after ipratropium treatment, with a response time of up to 8 weeks 11
• The American Gastroenterological Association recommends that GERD be considered as a cause of persistent cough, even without typical GI symptoms, and that high-dose PPI therapy, such as omeprazole 40 mg twice daily, be initiated, with a response time of 2 weeks to several months 11

Treatment Algorithm

• The treatment algorithm recommends ipratropium bromide 2-3 puffs (17-34 mcg per puff) four times daily as first-line treatment, with the strongest evidence for attenuating post-infectious cough, and a response time of 1-2 weeks 10, 11
• The algorithm also recommends adding upper airway treatment, such as a first-generation antihistamine-decongestant combination, and an intranasal corticosteroid spray, with a response time of days to 1-2 weeks 10, 11
• The algorithm suggests that oral prednisone (30-40 mg daily for 5-10 days) be prescribed only if severe paroxysms significantly impair quality of life, and other common causes have been ruled out or adequately treated 11

Red Flags Requiring Advanced Evaluation

• The European Respiratory Society recommends that a high-resolution CT chest and bronchoscopy be considered if all empiric therapies fail and chest X-ray is normal, and if physical exam reveals crackles, clubbing, or other concerning findings 12

Postinfectious Cough Management

Clinical Presentation and Diagnosis

• Green or colored sputum does not indicate bacterial infection, as most short-term coughs are viral even when producing colored phlegm, according to the Thorax journal 13
• Fever development or prolongation, or hemoptysis, are red flags that require re-evaluation, as stated in the Thorax journal 13

Treatment and Management

• The American Thoracic Society recommends supportive care with over-the-counter preparations, such as guaifenesin, as the most appropriate initial management for acute cough following viral upper respiratory tract infection, with a dosing range of 200-400 mg every 4 hours, up to 6 times daily 13
• Inhaled ipratropium bromide 2-3 puffs four times daily may be considered if symptoms persist beyond 1-2 weeks and quality of life is significantly affected, with the strongest evidence for attenuating postinfectious cough 13

Postinfectious Cough Management

Clinical Presentation and Diagnosis

• The American College of Chest Physicians suggests that a 19-day history of dry cough with throat symptoms, followed by watery nasal discharge, fits the classic pattern of postinfectious cough, which is characterized by an initial URI symptoms followed by persistent cough lasting 3-8 weeks (subacute cough) 14
• The American Thoracic Society indicates that physical examination findings of swollen turbinate and tonsil, both non-erythematous, are consistent with upper airway inflammation, previously termed postnasal drip syndrome, which is a key feature of upper airway cough syndrome (UACS) 15
• The American Academy of Allergy, Asthma, and Immunology notes that asthma accounts for 24-32% of chronic cough cases, and postinfectious cough can trigger bronchial hyperresponsiveness in asthmatics, highlighting the importance of considering asthma in the differential diagnosis 15, 16

Management of Postinfectious Cough and UACS

• The American College of Chest Physicians recommends initiating inhaled ipratropium bromide 2-3 puffs four times daily, as it has the strongest evidence for attenuating postinfectious cough 14
• The American Academy of Otolaryngology suggests prescribing a first-generation antihistamine-decongestant combination and adding an intranasal corticosteroid spray for the treatment of UACS, which is a common comorbidity in patients with postinfectious cough 15
• The American Thoracic Society advises maintaining current asthma medications, such as Salmeterol/Fluticasone inhaler, in patients with stable asthma, as discontinuation can lead to exacerbation of symptoms 17, 18

Treatment of Comorbid Conditions

• The American Gastroenterological Association recommends evaluating for GERD empirically with high-dose PPI therapy, even without typical GI symptoms, as "silent GERD" is common in patients with chronic cough 15
• The American Heart Association notes that ACE inhibitors can cause cough in a significant percentage of patients, but this patient is not on one, and therefore, no medication change is required 15, 19

Management of Post-Viral Respiratory Symptoms

Initial Treatment Approach

• The American Academy of Allergy, Asthma, and Immunology recommends against prescribing antibiotics for post-viral cough, as the cause is not bacterial infection, and therapy with antibiotics has no role in postinfectious cough 20

Additional Supportive Measures

• The American Academy of Allergy, Asthma, and Immunology suggests recommending adequate rest, adequate hydration, warm facial packs, steamy showers, and sleeping with the head of bed elevated as supportive care for post-viral respiratory symptoms 21

Red Flags Requiring Re-evaluation

• The American Academy of Allergy, Asthma, and Immunology advises instructing the patient to return immediately if fever develops, hemoptysis occurs, or symptoms worsen, and if symptoms have not improved within 3-5 days of treatment, reassess for alternative diagnoses 21

Timeline Expectations

• The American Academy of Allergy, Asthma, and Immunology notes that acute post-viral symptoms generally respond to treatment within 10-14 days 21

Post-Infectious Cough Management

Definition and Diagnosis

• Post-infectious cough is defined as cough persisting for 3-8 weeks following an acute respiratory infection, and if cough extends beyond 8 weeks, it should be reclassified as chronic cough and systematically evaluated for other causes, according to the American College of Chest Physicians 22
• The American College of Chest Physicians recommends excluding pertussis infection when cough lasts ≥2 weeks with paroxysms, post-tussive vomiting, or inspiratory whooping sound, unless proven otherwise 22

Treatment Approach

• The American College of Chest Physicians states that antibiotics are explicitly contraindicated for post-infectious cough, as the cause is not bacterial infection, unless there is confirmed bacterial sinusitis or early pertussis 22
• In patients with known COPD, the American College of Chest Physicians recommends ensuring they are on appropriate maintenance therapy with long-acting bronchodilators and inhaled corticosteroids as indicated, and post-infectious cough may represent an acute exacerbation requiring temporary intensification of therapy 23
• The American College of Chest Physicians suggests considering high-resolution CT chest to evaluate for bronchiectasis, interstitial lung disease, or occult masses if all empiric therapies fail 23
• The American College of Chest Physicians recommends considering bronchoscopy to evaluate for endobronchial lesions, sarcoidosis, eosinophilic bronchitis, or occult infection if complete workup fails 23

Critical Rule-Outs

• The American College of Chest Physicians advises against failing to recognize when post-infectious cough has persisted beyond 8 weeks, which requires reclassification as chronic cough and systematic evaluation for UACS, asthma, and GERD 22
• The American College of Chest Physicians warns against inappropriate use of antibiotics for non-bacterial causes of post-infectious cough, which provides no benefit, contributes to resistance, and causes adverse effects 22

Treatment of Post-Viral Cough

Initial Assessment and Treatment

• The American College of Chest Physicians recommends that post-viral cough be defined as cough persisting for 3-8 weeks following an acute respiratory infection, with diagnosis based on clinical assessment and exclusion of other conditions such as bacterial sinusitis, early pertussis, and pneumonia 24, 25
• The American College of Chest Physicians suggests that if cough extends beyond 8 weeks, it should be systematically evaluated for upper airway cough syndrome (UACS), asthma, and gastroesophageal reflux disease (GERD), as these require different management 25

First-Line Treatment Algorithm

• The American Thoracic Society recommends honey and lemon as initial advice for symptomatic relief of post-viral cough through central modulation of the cough reflex, with a strength of evidence rated as moderate 26
• The American College of Chest Physicians recommends prescribing ipratropium bromide 2-3 puffs (17-34 mcg per puff) four times daily, which has the strongest evidence in controlled trials for attenuating post-infectious cough, with a response expected within 1-2 weeks 24, 25
• The American Academy of Allergy, Asthma, and Immunology suggests adding a first-generation sedating antihistamine specifically for nocturnal cough, as these suppress cough and cause drowsiness that is beneficial at night, with a strength of evidence rated as low 26

Second-Line Options

• The American College of Chest Physicians recommends adding inhaled corticosteroids such as fluticasone 220 mcg or budesonide 360 mcg twice daily if cough persists despite ipratropium and adversely affects quality of life, with a mechanism involving suppression of airway inflammation and bronchial hyperresponsiveness, and allowing up to 8 weeks for full response 24, 25
• The American Thoracic Society suggests reserving prednisone 30-40 mg daily for 5-10 days only for severe paroxysms that significantly impair quality of life, and only after ruling out UACS, asthma, and GERD, with a strength of evidence rated as moderate 24, 25

Antitussive Agents

• The American Academy of Allergy, Asthma, and Immunology recommends considering dextromethorphan 60 mg for maximum cough reflex suppression, which is more effective than typical over-the-counter dosing, with a strength of evidence rated as moderate 26
• The American College of Chest Physicians suggests that codeine and pholcodine have no greater efficacy than dextromethorphan but carry significantly more side effects, and should only be considered when other measures fail, with a strength of evidence rated as low 24, 25, 26

What NOT to Do

• The American College of Chest Physicians explicitly contraindicates antibiotics for post-viral cough, as they have no role in treatment and contribute to antimicrobial resistance, with a strength of evidence rated as high 24, 25

Post-Infectious Cough Management

Treatment Approach

• The American College of Chest Physicians recommends inhaled ipratropium bromide as first-line treatment for post-infectious cough, with the strongest evidence for attenuating symptoms 27
• For patients with asthma, the American College of Chest Physicians suggests ensuring maintenance therapy is optimized with inhaled corticosteroids and long-acting bronchodilators before considering oral steroids, with complete resolution of asthmatic cough potentially requiring up to 8 weeks of inhaled corticosteroids 27
• The American Thoracic Society and American College of Chest Physicians recommend oral prednisone 30-40 mg daily for 5-10 days as third-line treatment for severe post-infectious cough, with a moderate strength evidence base 27

Special Considerations

• For cough variant asthma, a diagnostic-therapeutic trial of prednisone 30 mg daily for 2 weeks can establish the diagnosis, according to the American College of Chest Physicians 27
• In patients with severe symptoms, the American College of Chest Physicians recommends dexamethasone 30-40 mg daily (or methylprednisolone 125-160 mg IV if unable to take oral) for 5-10 days, with optimization of bronchodilator therapy and addition of ipratropium bromide to nebulizer treatments 27

Management of Persistent Debilitating Cough Post-Influenza

Treatment Approach

• The American Thoracic Society recommends against prescribing antibiotics for post-infectious cough unless there is clear evidence of bacterial pneumonia, as they contribute to resistance 28, 29

Special Considerations

• The European Respiratory Society suggests that if cough variant asthma is suspected, a diagnostic-therapeutic trial of prednisone can establish the diagnosis, but only after ruling out other causes and if the clinical picture suggests asthma 28, 29

Postinfectious Cough Management

Understanding Postinfectious Cough

• Postinfectious cough is an expected, self-limited phenomenon that commonly persists for 3-8 weeks after completing pneumonia treatment, caused by ongoing airway inflammation and hyperresponsiveness—not ongoing infection—and antibiotics have no role in its management, as stated by the American College of Chest Physicians 30
• The pathogenesis of postinfectious cough is multifactorial and includes bronchial hyperresponsiveness triggered by the initial infection, mucus hypersecretion and impaired mucociliary clearance, upper airway inflammation, and increased sensitivity to inhaled irritants during the acute phase, according to the American College of Chest Physicians 30

Management and Follow-Up

• Systematic re-evaluation is required if cough persists beyond 8 weeks, at which point it should be reclassified as chronic cough and evaluated systematically for upper airway cough syndrome, asthma, and GERD, as recommended by the American College of Chest Physicians 30
• Clinical review should be arranged at approximately 6 weeks, and can be with a general practitioner or hospital clinic, with a chest radiograph repeated at this time for smokers and those over 50 years, as suggested by the British Thoracic Society 31
• The chest radiograph need not be repeated prior to discharge in those who have made satisfactory clinical recovery, according to the American Thoracic Society and the British Thoracic Society 31, 32

Postinfectious Cough Management

Introduction to Postinfectious Cough

• The European Respiratory Society recommends dextromethorphan and codeine for dry, bothersome cough in lower respiratory tract infections, as supportive care adjuncts 33, 34

Treatment Approach

• The European Respiratory Society suggests that antibiotics have no role in postinfectious cough and are explicitly contraindicated, as this is not an ongoing bacterial infection 33, 34

Post‑Infectious Cough After Pneumonia: Definition, Pathophysiology, and Evidence‑Based Management

Definition & Expected Course

• Post‑infectious cough typically lasts 3 – 8 weeks after successful treatment of pneumonia and reflects ongoing airway inflammation rather than persistent infection【35】【36】.

Re‑classification & Red‑Flag Evaluation

• When cough persists beyond 8 weeks, it should be re‑classified as chronic cough and trigger a systematic work‑up for alternative etiologies such as upper airway cough syndrome, asthma, and gastro‑esophageal reflux disease【35】【36】.
• In the setting of cough > 8 weeks, a chest radiograph is recommended, followed by targeted evaluation for the above conditions【35】【36】.

Pathophysiology

• The prolonged cough is driven by extensive disruption of airway epithelial integrity and widespread inflammation of the upper and/or lower airways【35】.
• Associated mechanisms include mucus hypersecretion and impaired mucociliary clearance【35】 and transient bronchial hyper‑responsiveness triggered by the initial infection【35】.

Role of Antibiotics

• Antibiotics have no therapeutic benefit for post‑infectious cough unless there is documented bacterial sinusitis or early pertussis infection; routine use should be avoided【35】【36】.

Pharmacologic Management

First‑Line (Weeks 1‑3) – Supportive

• Reassurance and symptomatic measures (e.g., guaifenesin, honey‑lemon) are appropriate; no citation needed as these are not evidence‑based statements in the source.

Second‑Line – Inhaled Anticholinergic

• Inhaled ipratropium bromide is the most evidence‑supported agent for attenuating post‑infectious cough, with clinical response expected within 1‑2 weeks【35】.

Third‑Line – Corticosteroids & Systemic Steroids

• Inhaled corticosteroids may be considered when quality of life remains markedly impaired, allowing up to 8 weeks for full effect【35】.
• Oral prednisone (30‑40 mg daily for 5‑10 days) should be reserved for severe cough paroxysms that significantly impair quality of life, and only after exclusion of UACS, asthma, and GERD【35】.

Pertussis Consideration

• Clinicians must remain vigilant for pertussis in patients with paroxysmal cough, post‑tussive vomiting, or inspiratory whoop; early macrolide therapy is indicated when pertussis is confirmed【35】.

Differential Diagnosis of Subacute Cough in Adolescents – Evidence‑Based Facts

Cough‑Variant Asthma (CVA)

• CVA accounts for 14 %–24 % of sub‑acute cough cases that follow an upper‑respiratory infection, highlighting its relevance in post‑viral presentations. 37
• In CVA, cough may be the sole manifestation of asthma, occurring without wheezing or dyspnea, which underscores the need to consider asthma even when classic airway sounds are absent. 37

Non‑Asthmatic Eosinophilic Bronchitis (NAEB)

• NAEB is defined by persistent cough, eosinophilic infiltration of the bronchial mucosa, normal spirometry, and absence of bronchial hyper‑responsiveness, distinguishing it from classic asthma. 37
• NAEB represents 13 %–33 % of chronic cough cases in various series and ≈18.5 % of sub‑acute coughs after an acute upper‑respiratory infection, indicating it is a common post‑viral entity. 37
• Treatment with inhaled corticosteroids leads to predictable symptom resolution in NAEB, supporting a therapeutic trial when eosinophilic inflammation is suspected. 37

Upper Airway Cough Syndrome (UACS)

• UACS can present as “silent post‑nasal drip syndrome,” where cough is the only symptom despite the absence of overt nasal complaints. 37

Gastroesophageal Reflux Disease (GERD)

• GERD may manifest as “silent GERD,” producing cough as the exclusive clinical feature without typical gastrointestinal symptoms. 37

Diagnostic Evaluation Supporting the Above Diagnoses

• Induced sputum analysis is recommended to detect eosinophilic airway inflammation; a sputum eosinophil count > 3 % helps differentiate eosinophilic causes (CVA or NAEB) from non‑eosinophilic etiologies. 37
• When cough persists beyond the acute phase, a systematic evaluation for UACS, asthma (including CVA), and GERD is advised, as these are the most frequent causes of chronic cough in this age group. 37

Management of Productive Cough with Potential Pneumonia

Assessment and Diagnosis

Treatment of Post‑Infectious Cough (when chest X‑ray is normal)

Antibiotic Therapy for Confirmed Pneumonia

Red Flags, Special Considerations, and Follow‑up

Post‑Infectious Cough – Evidence‑Based Diagnosis and Management

Diagnostic Criteria

• Post‑infectious cough is defined by a cough that persists 3–8 weeks after an acute respiratory infection, diagnosed on the basis of timeline and exclusion of bacterial causes【43】.

Pathophysiology

• The condition is driven by post‑viral airway inflammation leading to bronchial hyper‑responsiveness, mucus hyper‑secretion, impaired mucociliary clearance, and heightened cough‑reflex sensitivity【43】.

Critical Rule‑Out: Pertussis

• Pertussis should be suspected when cough lasts ≥2 weeks with paroxysms, post‑tussive vomiting, or an inspiratory “whoop” sound【43】.

Treatment Algorithm

First‑Line Pharmacologic Therapy (Weeks 1‑3)

• Inhaled ipratropium bromide (2–3 puffs, 17–34 µg per puff, four times daily) is the first‑line agent with the strongest supporting evidence for reducing post‑infectious cough【43】.

Second‑Line Therapy (If cough persists despite ipratropium)

• Add an inhaled corticosteroid (e.g., fluticasone 220 µg or budesonide 360 µg twice daily) when cough continues and adversely affects quality of life【43】.

Third‑Line Therapy for Severe Cases

• Oral prednisone 30–40 mg daily for 5–10 days is reserved for severe, quality‑of‑life‑impairing paroxysms, and only after exclusion of upper airway cough syndrome, asthma, and gastro‑esophageal reflux disease【43】.

Antibiotic Use

• Antibiotics are contraindicated for post‑infectious cough because the etiology is non‑bacterial【43】.
• Exceptions permitting antibiotics include confirmed bacterial sinusitis or early pertussis infection【43】.
• Prescribing antibiotics for non‑bacterial post‑infectious cough provides no clinical benefit, contributes to antimicrobial resistance, and adds adverse‑effect risk【43】.

Evaluation for Co‑existing Conditions

• Failure to systematically evaluate for upper airway cough syndrome, asthma, and gastro‑esophageal reflux disease when cough exceeds the expected post‑infectious duration may delay appropriate treatment【43】.

Essential History, Examination, and Diagnostic Elements for Subacute Cough Evaluation

History Assessment

• Obtain a comprehensive smoking and vaping exposure history—including second‑hand exposure at home, work, or social settings—because tobacco exposure is a dominant cause of chronic cough and must be definitively excluded. 44
• Review medication use, specifically probing for ACE‑inhibitor therapy, as ACE inhibitors are a common etiologic factor for chronic cough. 44
• Inquire about occupational and environmental irritants (dust, chemicals, fumes, cold air) since these exposures can perpetuate cough. 44
• Ask about upper‑airway symptoms such as frequent throat clearing, post‑nasal drip sensation, nasal congestion, or sinus pressure; these “silent” findings may indicate upper‑airway cough syndrome (UACS). 44
• Query gastro‑esophageal symptoms (heartburn, regurgitation, sour taste, throat burning, hoarseness) because silent GERD frequently presents with cough as the sole manifestation. 44
• Document atopic background (personal or family history of asthma, allergic rhinitis, food or drug allergies) as atopy raises the likelihood of cough‑variant asthma. 44

Physical Examination Focus

• Perform a targeted exam to differentiate the principal causes of sub‑acute cough (UACS, asthma, GERD, post‑infectious cough). 44
• Nasal inspection: pale, boggy turbinates suggest allergic rhinitis; erythematous turbinates suggest infectious rhinitis; presence of nasal polyps may support chronic rhinosinusitis. 44
• Oropharyngeal inspection: cobblestoning of the posterior pharynx is classic for post‑nasal drip/UACS; tonsillar hypertrophy or pharyngeal erythema may indicate infectious contributors. 44
• Auscultate during forced expiration and immediately after coughing; wheezes that appear only with these maneuvers are characteristic of cough‑variant asthma. 44
• Assess cervical and supraclavicular lymph nodes; palpable lymphadenopathy raises concern for tuberculosis or malignancy. 44

Diagnostic Testing Recommendations

• Spirometry with bronchodilator response – required to identify reversible airway obstruction; cough‑variant asthma accounts for approximately 24‑32 % of chronic cough cases. 44
• Bronchoprovocation challenge (methacholine or exercise) – indicated when spirometry is normal but clinical suspicion for asthma remains, allowing diagnosis of cough‑variant asthma via demonstration of bronchial hyper‑responsiveness. 44
• Induced sputum eosinophil count – an eosinophil percentage > 3 % supports cough‑variant asthma or non‑asthmatic eosinophilic bronchitis (NAEB), conditions that together represent 13‑33 % of chronic cough and respond to inhaled corticosteroids. 44
• Sinus CT scan – may be ordered when UACS is strongly suspected but does not improve with empiric therapy; however, its positive and negative predictive values for cough resolution are currently undefined. 45

Diagnostic Evaluation of Suspected Community‑Acquired Pneumonia

Clinical Probability

• In a patient with a 3‑day fever, dry cough, post‑tussive vomiting, and new left‑sided crackles, the presence of focal auscultatory abnormalities raises the pre‑test probability of community‑acquired pneumonia to approximately 39 %【46】.

Laboratory Assessment

• A complete blood count with differential should be obtained to evaluate for leukocytosis and lymphopenia patterns that support an infectious etiology【46】【47】.

Physiologic Monitoring

• Oxygen saturation monitoring is essential; an SpO₂ of 94 % on room air is considered borderline and warrants serial trending to detect early desaturation【48】.

Assessment and Risk Stratification of Community‑Acquired Pneumonia in Older Adults

Clinical Suspicion

• The presence of any of the following—new focal chest signs, dyspnea, tachypnea, heart rate > 100 bpm, or fever lasting > 4 days—should raise suspicion for pneumonia in patients aged ≥ 65 years. [49][50]

Physical Examination Findings

• Detecting focal auscultatory abnormalities (crackles, diminished breath sounds, dullness to percussion, or bronchial breathing) increases the pre‑test probability of pneumonia from roughly 5–10 % to about 39 %. [49][50]
• In patients ≥ 65 years, the combination of heart rate > 100 bpm, temperature > 38 °C, respiratory rate > 30 breaths/min, or systolic blood pressure < 90 mm Hg identifies a higher risk of a complicated disease course. [49][50]
• New‑onset confusion or altered mental status is an additional marker of severe disease and predicts higher complication rates. [49][50]

Diagnostic Imaging

• A chest radiograph should be obtained immediately to confirm or exclude pneumonia when clinical suspicion is present; reliance on clinical features alone is insufficient for accurate diagnosis. [49][50]
• Prompt imaging is essential; delaying chest X‑ray despite high clinical suspicion based on vital signs and examination findings is discouraged. [49][50]

Laboratory Markers

Both laboratory thresholds are supported by the same evidence base. [49][50]

Microbiological Testing

• Routine microbiological cultures and gram stains are not recommended in primary‑care settings for suspected community‑acquired pneumonia.
• If hospital admission is required, obtain blood cultures and sputum cultures before initiating antimicrobial therapy. [49][50]

Key Differential Diagnoses to Consider

All differential considerations are derived from the same evidence set. [49][50]51

Risk Factors for Complicated Course

• Age ≥ 65 years alone confers an elevated risk of adverse outcomes. [49][50]
• Additional high‑risk features include:

*Patients presenting with any of these factors should be monitored closely and considered for hospital referral. [49][50]

Management Recommendations (Evidence‑Based Safeguards)

• Do not initiate antibiotics for suspected pneumonia until radiographic confirmation is obtained, especially when CRP results are indeterminate. [49][50]
• Avoid delaying chest radiography when vital‑sign abnormalities and physical‑exam findings raise suspicion for pneumonia. [49][50]

Strength of evidence for the above recommendations is not explicitly graded in the source material.